Our findings, although they do not correspond to the current global COVID-19 situation, corroborate the importance of maintaining an early healthy balance between pro-inflammatory and anti-inflammatory mechanisms in SARS-CoV-2 infection to prevent these clinical complications or when developing IgA monoclonal antibodies (mAbs) as a therapeutic option [37]. The gene discussed is CD79A; the disease is COVID-19.